<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02614521</url>
  </required_header>
  <id_info>
    <org_study_id>2015-IIS-GR-AF</org_study_id>
    <nct_id>NCT02614521</nct_id>
  </id_info>
  <brief_title>Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Paroxysmal Atrial Fibrillation</brief_title>
  <official_title>A Single-center, Observational, 12-months Study to Examine the Predictive Factors for Successful Outcome After Pulmonary Veins Ablation to Treat Patients With Paroxysmal Atrial Fibrillation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Elpen Pharmaceutical Co. Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Elpen Pharmaceutical Co. Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation is the most common serious abnormal heart rhythm affecting about 2% to 3%
      of the population, being associated with a 1.5- to 1.9-fold higher risk of death. Patients
      with paroxysmal AF in whom antiarrhythmic drug therapy does not elicit a response are
      potential candidates for RF ablation of AF. The success rate of RF ablation in the treatment
      of AF varies depending on the type and duration of AF (ie, paroxysmal vs persistent),
      structural remodeling of the heart, co-morbidities and the technique of the cardiac
      electrophysiologist, but it usually ranges from 60-80% over 1-2 years of follow-up.

      To study and predict the successful outcome of RF ablation is of great clinical importance.
      Moreover, the detection of predictive factors for successful outcome may alter the
      therapeutic strategy determining a subgroup of patients in the need of more invasive
      management.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will include 150 patients scheduled to undergo pulmonary vein (PV) ablation because
      of non-responsive to medical therapy PAF. ECG recordings will be obtained during sinus rhythm
      before and after PV ablation with a 3 - channel digital recorder for 10 minutes, and
      digitized with a 16-bit accuracy at a sampling rate of 1000 Hz. The P wave will be analyzed
      using the Morlet wavelet. Other parameters to be analyzed include 12 lead surface ECG, the
      burden of main and secondary morphologies and echocardiographic indexes of left atrial
      mechanical function. Follow-up visits will be held in 3, 6 and 12 months after the ablation
      procedure.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2017</start_date>
  <completion_date type="Anticipated">September 2018</completion_date>
  <primary_completion_date type="Anticipated">September 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Paroxysmal Atrial Fibrillation (PAF) relapse(s)</measure>
    <time_frame>12 months</time_frame>
    <description>Primary end point is one or more PAF relapse(s) during a period of 12 months after the ablation procedure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Adverse Events</measure>
    <time_frame>12 months</time_frame>
    <description>Adverse Events occurred during study period</description>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Atrial Fibrillation</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pulmonary veins ablation's successful outcome</intervention_name>
    <description>Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with paroxysmal atrial fibrillation
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Males and Females

          -  Age &gt;18 years

          -  Paroxysmal AF (PAF) scheduled to undergo pulmonary vein (PV) ablation

          -  Singed written consent form

          -  Patients who will comply with study procedures

        Exclusion Criteria:

          -  Age &lt;18 years Permanent atrial fibrillation

          -  Acute myocardial infraction, coronary artery bypass graft surgery or percutaneous
             transluminal coronary angioplasty within less than 2 months prior to ablation
             procedure

          -  Life expectancy less than 12 months, according to investigator's judgment

          -  Participation to other clinical trial

          -  Patients who will not be compliant with study procedures
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vassilios P Vassilikos, MD, FACC</last_name>
    <role>Study Chair</role>
    <affiliation>Aristoteleion University of Thessaloniki, Hippokrateion Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vassilios P Vassilikos, MD, FACC</last_name>
    <phone>00302301272032</phone>
    <email>vvassil@med.auth.gr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hippokrateion University Hospital</name>
      <address>
        <city>Thessaloniki</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ioannis Tsanakas, MD Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <reference>
    <citation>Pappone C, Rosanio S, Oreto G, Tocchi M, Gugliotta F, Vicedomini G, Salvati A, Dicandia C, Mazzone P, Santinelli V, Gulletta S, Chierchia S. Circumferential radiofrequency ablation of pulmonary vein ostia: A new anatomic approach for curing atrial fibrillation. Circulation. 2000 Nov 21;102(21):2619-28.</citation>
    <PMID>11085966</PMID>
  </reference>
  <reference>
    <citation>Liu X, Long D, Dong J, Hu F, Yu R, Tang R, Fang D, Hao P, Lu C, Liu X, He X, Liu X, Ma C. Is circumferential pulmonary vein isolation preferable to stepwise segmental pulmonary vein isolation for patients with paroxysmal atrial fibrillation? Circ J. 2006 Nov;70(11):1392-7.</citation>
    <PMID>17062959</PMID>
  </reference>
  <reference>
    <citation>Ouyang F, Antz M, Ernst S, Hachiya H, Mavrakis H, Deger FT, Schaumann A, Chun J, Falk P, Hennig D, Liu X, Bänsch D, Kuck KH. Recovered pulmonary vein conduction as a dominant factor for recurrent atrial tachyarrhythmias after complete circular isolation of the pulmonary veins: lessons from double Lasso technique. Circulation. 2005 Jan 18;111(2):127-35. Epub 2004 Dec 27.</citation>
    <PMID>15623542</PMID>
  </reference>
  <reference>
    <citation>Oral H. Mechanisms of atrial fibrillation: lessons from studies in patients. Prog Cardiovasc Dis. 2005 Jul-Aug;48(1):29-40. Review.</citation>
    <PMID>16194690</PMID>
  </reference>
  <reference>
    <citation>Pappone C, Santinelli V, Manguso F, Vicedomini G, Gugliotta F, Augello G, Mazzone P, Tortoriello V, Landoni G, Zangrillo A, Lang C, Tomita T, Mesas C, Mastella E, Alfieri O. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004 Jan 27;109(3):327-34. Epub 2004 Jan 5.</citation>
    <PMID>14707026</PMID>
  </reference>
  <reference>
    <citation>Xia Y, Hertervig E, Kongstad O, Ljungström E, Platonov P, Holm M, Olsson B, Yuan S. Deterioration of interatrial conduction in patients with paroxysmal atrial fibrillation: electroanatomic mapping of the right atrium and coronary sinus. Heart Rhythm. 2004 Nov;1(5):548-53. Erratum in: Heart Rhythm. 2005 Dec;2(12):1395. Pyotr, Platonov [corrected to Platonov, Pyotr].</citation>
    <PMID>15851217</PMID>
  </reference>
  <reference>
    <citation>Byrd GD, Prasad SM, Ripplinger CM, Cassilly TR, Schuessler RB, Boineau JP, Damiano RJ Jr. Importance of geometry and refractory period in sustaining atrial fibrillation: testing the critical mass hypothesis. Circulation. 2005 Aug 30;112(9 Suppl):I7-13.</citation>
    <PMID>16159868</PMID>
  </reference>
  <reference>
    <citation>Van Beeumen K, Houben R, Tavernier R, Ketels S, Duytschaever M. Changes in P-wave area and P-wave duration after circumferential pulmonary vein isolation. Europace. 2010 Jun;12(6):798-804. doi: 10.1093/europace/eup410. Epub 2010 Jan 3.</citation>
    <PMID>20047928</PMID>
  </reference>
  <reference>
    <citation>Blanche C, Tran N, Rigamonti F, Burri H, Zimmermann M. Value of P-wave signal averaging to predict atrial fibrillation recurrences after pulmonary vein isolation. Europace. 2013 Feb;15(2):198-204. doi: 10.1093/europace/eus251. Epub 2012 Aug 31.</citation>
    <PMID>22941968</PMID>
  </reference>
  <reference>
    <citation>Morlet D, Peyrin F, Desseigne P, Touboul P, Rubel P. Wavelet analysis of high-resolution signal-averaged ECGs in postinfarction patients. J Electrocardiol. 1993 Oct;26(4):311-20.</citation>
    <PMID>8228720</PMID>
  </reference>
  <reference>
    <citation>Vassilikos V, Dakos G, Chatzizisis YS, Chouvarda I, Karvounis C, Maynard C, Maglaveras N, Paraskevaidis S, Stavropoulos G, Styliadis CI, Mochlas S, Styliadis I. Novel non-invasive P wave analysis for the prediction of paroxysmal atrial fibrillation recurrences in patients without structural heart disease: a prospective pilot study. Int J Cardiol. 2011 Dec 1;153(2):165-72. doi: 10.1016/j.ijcard.2010.08.029. Epub 2010 Sep 15.</citation>
    <PMID>20837368</PMID>
  </reference>
  <reference>
    <citation>Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P; ESC Committee for Practice Guidelines (CPG). 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47. doi: 10.1093/eurheartj/ehs253. Epub 2012 Aug 24. Erratum in: Eur Heart J. 2013 Mar;34(10):790. Eur Heart J. 2013 Sep;34(36):2850-1.</citation>
    <PMID>22922413</PMID>
  </reference>
  <reference>
    <citation>Martínez A, Alcaraz R, Rieta JJ. Application of the phasor transform for automatic delineation of single-lead ECG fiducial points. Physiol Meas. 2010 Nov;31(11):1467-85. doi: 10.1088/0967-3334/31/11/005. Epub 2010 Sep 24.</citation>
    <PMID>20871135</PMID>
  </reference>
  <reference>
    <citation>Packer DL, Kowal RC, Wheelan KR, Irwin JM, Champagne J, Guerra PG, Dubuc M, Reddy V, Nelson L, Holcomb RG, Lehmann JW, Ruskin JN; STOP AF Cryoablation Investigators. Cryoballoon ablation of pulmonary veins for paroxysmal atrial fibrillation: first results of the North American Arctic Front (STOP AF) pivotal trial. J Am Coll Cardiol. 2013 Apr 23;61(16):1713-23. doi: 10.1016/j.jacc.2012.11.064. Epub 2013 Mar 21.</citation>
    <PMID>23500312</PMID>
  </reference>
  <reference>
    <citation>Ketels S, Houben R, Van Beeumen K, Tavernier R, Duytschaever M. Incidence, timing, and characteristics of acute changes in heart rate during ongoing circumferential pulmonary vein isolation. Europace. 2008 Dec;10(12):1406-14. doi: 10.1093/europace/eun287. Epub 2008 Oct 19.</citation>
    <PMID>18936041</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 23, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 25, 2015</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pulmonary veins ablation</keyword>
  <keyword>Paroxysmal atrial fibrillation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

